{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:00:23Z","timestamp":1793278823542,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.molmed.2022.02.011","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T22:21:19Z","timestamp":1648160479000},"page":"378-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Choroideremia: molecular mechanisms and therapies"],"prefix":"10.1016","volume":"28","author":[{"given":"Hajrah","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Moosajee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2022.02.011_bb0005","article-title":"Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments","volume":"10","author":"Mitsios","year":"2018","journal-title":"Ther. Adv. Ophthalmol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0010","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ejhg.2013.183","article-title":"Clinical utility gene card for: choroideremia","volume":"22","author":"Moosajee","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0015","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2009.01.016","article-title":"Fundus autofluorescence in carriers of choroideremia and correlation with electrophysiologic and psychophysical data","volume":"116","author":"Preising","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.molmed.2022.02.011_bb0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13816810490514333","article-title":"Rab escort protein 1 (REP1) in intracellular traffic: a functional and pathophysiological overview","volume":"25","author":"Preising","year":"2004","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/hmg\/1.2.71","article-title":"An autosomal homologue of the choroideremia gene colocalizes with the usher syndrome type II locus on the distal part of chromosome 1q","volume":"1","author":"Cremers","year":"1992","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0030","doi-asserted-by":"crossref","first-page":"24420","DOI":"10.1074\/jbc.270.41.24420","article-title":"Deficient geranylgeranylation of Ram\/Rab27 in choroideremia","volume":"270","author":"Seabra","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2022.02.011_bb0035","doi-asserted-by":"crossref","first-page":"46798","DOI":"10.1074\/jbc.M307799200","article-title":"Multiple factors contribute to inefficient prenylation of Rab27a in Rab prenylation diseases","volume":"278","author":"Larijani","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.molmed.2022.02.011_bb0040","doi-asserted-by":"crossref","first-page":"e81758","DOI":"10.1371\/journal.pone.0081758","article-title":"Rab GTPase prenylation hierarchy and its potential role in choroideremia disease","volume":"8","author":"K\u00f6hnke","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2022.02.011_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/opo.12023","article-title":"An internet-based health survey on the co-morbidities of choroideremia patients","volume":"33","author":"Zhou","year":"2013","journal-title":"Ophthalmic Physiol. Opt."},{"key":"10.1016\/j.molmed.2022.02.011_bb0050","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1167\/iovs.14-15751","article-title":"Choroideremia is a systemic disease with lymphocyte crystals and plasma lipid and RBC membrane abnormalities","volume":"56","author":"Zhang","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.molmed.2022.02.011_bb0055","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1167\/iovs.18-25112","article-title":"Crystals and fatty acid abnormalities are not present in circulating cells from choroideremia patients","volume":"59","author":"Radziwon","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.molmed.2022.02.011_bb0060","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146934","article-title":"REP1 deficiency causes systemic dysfunction of lipid metabolism and oxidative stress in choroideremia","volume":"6","author":"Cunha","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2022.02.011_bb0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrm.2017.107","article-title":"Sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/13816810.2019.1660379","article-title":"Sj\u00f6gren\u2013Larsson syndrome: a complex metabolic disease with a distinctive ocular phenotype","volume":"40","author":"Fouzdar-Jain","year":"2019","journal-title":"Ophthalmic Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0075","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1093\/hmg\/ddw184","article-title":"Functional rescue of REP1 following treatment with PTC124 and novel derivative PTC-414 in human choroideremia fibroblasts and the nonsense-mediated zebrafish model","volume":"25","author":"Moosajee","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0080","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2174\/157015909787602823","article-title":"Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options","volume":"7","author":"Uttara","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0085","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/antiox9040347","article-title":"The relevance of oxidative stress in the pathogenesis and therapy of retinal dystrophies","volume":"9","author":"Dom\u00e8nech","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.molmed.2022.02.011_bb0090","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.3390\/ijms20092288","article-title":"The serotonin syndrome: from molecular mechanisms to clinical practice","volume":"20","author":"Francescangeli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2022.02.011_bb0095","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.molmed.2022.02.011_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.biochi.2018.11.006","article-title":"Serotonin in retina","volume":"161","author":"Masson","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.molmed.2022.02.011_bb0105","doi-asserted-by":"crossref","first-page":"e1000229","DOI":"10.1371\/journal.pbio.1000229","article-title":"Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation","volume":"7","author":"Paulmann","year":"2009","journal-title":"PLoS Biol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0110","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.molmed.2022.02.011_bb0115","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1476-5381.2011.01270.x","article-title":"Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus","volume":"163","author":"Dostalek","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/83a88285-e6a0-41fb-ae67-4315c21e5090","article-title":"Conditional ablation of the choroideremia gene causes age-related changes in mouse retinal pigment epithelium","volume":"8","author":"Wavre-Shapton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2022.02.011_bb0125","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1056\/NEJMc1509501","article-title":"Visual acuity after retinal gene therapy for choroideremia","volume":"374","author":"Edwards","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2022.02.011_bb0130","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.molmed.2022.02.011_bb0135","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2022.02.011_bb0140","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/IAE.0000000000002360","article-title":"Changes in retinal sensitivity after gene therapy in choroideremia","volume":"40","author":"Fischer","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.molmed.2022.02.011_bb0145","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results after AAV2-mediated gene therapy for choroideremia: The Alberta experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0155","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J. Ophthalmol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0160","first-page":"5173","article-title":"AAV2-hCHM subretinal delivery to the macula in choroideremia: 2 year results of an ongoing phase I\/II gene therapy trial","volume":"60","author":"Aleman","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.molmed.2022.02.011_bb0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.exer.2017.01.001","article-title":"Mechanism and evidence of nonsense suppression therapy for genetic eye disorders","volume":"155","author":"Richardson","year":"2017","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.molmed.2022.02.011_bb0170","doi-asserted-by":"crossref","first-page":"8234","DOI":"10.1038\/s41598-018-26481-7","article-title":"The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy","volume":"8","author":"Torriano","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2022.02.011_bb0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0968-0004(98)01208-0","article-title":"A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance","volume":"23","author":"Nagy","year":"1998","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.molmed.2022.02.011_bb0180","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1093\/hmg\/ddz028","article-title":"Nonsense-mediated mRNA decay efficiency varies in choroideremia providing a target to boost small molecule therapeutics","volume":"28","author":"Sarkar","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103515","article-title":"Translational readthrough of ciliopathy genes BBS2 and ALMS1 restores protein, ciliogenesis and function in patient fibroblasts","volume":"70","author":"Eintracht","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.molmed.2022.02.011_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2012.3","article-title":"Antisense oligonucleotide (AON)-based therapy for Leber congenital amaurosis caused by a frequent mutation in CEP290","volume":"1","author":"Collin","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.molmed.2022.02.011_bb0195","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3390\/ijms19030753","article-title":"Antisense oligonucleotide-based splicing correction in individuals with Leber congenital amaurosis due to compound heterozygosity for the c.2991+1655A>G mutation in CEP290","volume":"19","author":"Duijkers","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.molmed.2022.02.011_bb0200","first-page":"2552","article-title":"In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery","volume":"25","author":"Garanto","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2022.02.011_bb0205","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-319-75402-4_11","article-title":"Antisense oligonucleotide-based splice correction of a deep-intronic mutation in CHM underlying choroideremia","volume":"1074","author":"Garanto","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.molmed.2022.02.011_bb0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/glycob\/cwv084","article-title":"Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling","volume":"26","author":"Binnington","year":"2016","journal-title":"Glycobiology"},{"key":"10.1016\/j.molmed.2022.02.011_bb0215","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41433-020-0974-1","article-title":"Prospective deep phenotyping of choroideremia patients using multimodal structure\u2013function approaches","volume":"35","author":"Hagag","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.molmed.2022.02.011_bb0220","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/jcm10020232","article-title":"Longitudinal study to assess the quantitative use of fundus autofluorescence for monitoring disease progression in choroideremia","volume":"10","author":"Dubis","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.molmed.2022.02.011_bb0225","doi-asserted-by":"crossref","first-page":"14011","DOI":"10.1038\/mtm.2014.11","article-title":"Proof of concept for AAV2\/5-mediated gene therapy in iPSC-derived retinal pigment epithelium of a choroideremia patient","volume":"1","author":"Cereso","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2022.02.011_bb0230","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1172\/JCI132990","article-title":"Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial","volume":"130","author":"Campochiaro","year":"2020","journal-title":"J. Clin. Invest."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491422000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:24:54Z","timestamp":1761463494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491422000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S1471491422000521"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2022.02.011","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Choroideremia: molecular mechanisms and therapies","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2022.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}